
Regimen Monograph

 Regimen Name
 Drug Regimen
 Cycle Frequency
 Premedication and Supportive Measures
 Dose Modifications
 Adverse

 Effects
 Interactions
 Drug Administration and Special Precautions
 Recommended Clinical Monitoring
 Administrative

 Information
 References
 Other Notes
 Disclaimer

A - Regimen Name



back to top

Any use of the information is subject, at all times, to CCO's Terms and Conditions.

B - Drug Regimen

nivolumab / relatlimab ¹	480 mg /160 mg	IV	Day 1
-------------------------------------	----------------	----	-------

(This drug is not currently publicly funded for this regimen and intent)

¹Available as a combination concentrate solution with nivolumab 12 mg/mL and relatlimab 4 mg/mL

back to top

C - Cycle Frequency

REPEAT EVERY 28 DAYS

Until disease progression or unacceptable toxicity

back to top

D - Premedication and Supportive Measures

Antiemetic Regimen: Minimal

Pre-medications (prophylaxis for infusion reaction):

- Routine pre-medication is not recommended.
- May consider pre-medication with antipyretics and H1-receptor antagonists if an IR has occurred in the past.

Other Supportive Care:

- Also refer to <u>CCO Antiemetic Recommendations</u>.
- Screen for hepatitis B virus in all cancer patients starting systemic treatment. Refer to the hepatitis B virus screening and management guideline.

back to top

K - References

Product Monograph: Nivolumab / relatlimab (Opdualag™), September 2023.

Tawbi HA, Schadendorf D, Lipson EJ, et al. RELATIVITY-047 Investigators. Relatimab and nivolumab versus nivolumab in untreated advanced melanoma. N Engl J Med 2022 Jan 6;386(1):24-34.

July 2024 new ST-QBP regimen

back to top

M - Disclaimer

Regimen Abstracts

A Regimen Abstract is an abbreviated version of a Regimen Monograph and contains only top level information on usage, dosing, schedule, cycle length and special notes (if available). It is intended for healthcare providers and is to be used for informational purposes only. It is not intended to constitute or be a substitute for medical advice, and all uses of the Regimen Abstract are subject to clinical judgment. Such information is provided on an "as-is" basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information's quality, accuracy, currency, completeness, or reliability, and Cancer Care Ontario disclaims all liability for the use of this information, and for any claims, actions, demands or suits that arise from such use.

Information in regimen abstracts is accurate to the extent of the ST-QBP regimen master listings, and has not undergone the full review process of a regimen monograph. Full regimen monographs will be published for each ST-QBP regimen as they are developed.

Regimen Monographs

Refer to the <u>New Drug Funding Program</u> or <u>Ontario Public Drug Programs</u> websites for the most up-to-date public funding information.

The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.

The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.

Any use of the information is subject, at all times, to CCO's Terms and Conditions.

Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.

While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an "as-is" basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information's quality, accuracy, currency, completeness, or reliability.

CCO and the Formulary's content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person's use of the information in the Formulary.

back to top

Any use of the information is subject, at all times, to CCO's Terms and Conditions.